Zealand Pharma AS (ZLDPF)
(Delayed Data from OTC)
$93.70 USD
-3.30 (-3.40%)
Updated Jun 7, 2024 01:23 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZLDPF 93.70 -3.30(-3.40%)
Will ZLDPF be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ZLDPF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLDPF
Computer Programs and Systems (CPSI) Q3 Earnings Beat Estimates
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
ZLDPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novavax (NVAX) Q2 Earnings and Revenues Top Estimates
BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates
Zealand Pharma A/S (ZLDPF) is on the Move, Here's Why the Trend Could be Sustainable
Other News for ZLDPF
Zealand, Boehringer liver disease drug survodutide shows fibrosis improvement
SA Asks: Which weight-loss stocks should investors be watching?
Zealand Pharma announces positive CHMP opinion for dasiglucagon
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo